Spanish consensus statement on alternatives to allogeneic blood transfusion: The 2013 update of the "Seville Document"

Blood Transfusion

Volumn 11, Issue 4, 2013, Pages 585-610

  Leal Noval, Santiago R ^a   Muñoz, Manuel ^a   Asuero, Marisol ^a   Contreras, Enric ^a   García Erce, José A ^a   Llau, Juan V ^a   Moral, Victoria ^a   Páramo, José A ^a   Quintana, Manuel ^a  

^a Spanish Societies of Anaesthesiology and Reanimation ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIANEMIC AGENT; ANTIVITAMIN K; FIBRINOGEN CONCENTRATE; IRON; PROTHROMBIN COMPLEX; TRANEXAMIC ACID;

ABDOMINAL AORTA ANEURYSM; ADJUVANT THERAPY; ALLOGENEIC BLOOD TRANSFUSION; ANEURYSM SURGERY; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CANCER PATIENT; CANCER SURGERY; CARDIOPULMONARY BYPASS; CESAREAN SECTION; CONFERENCE PAPER; CONSENSUS; ECTOPIC PREGNANCY; FLUID RESUSCITATION; GASTROINTESTINAL HEMORRHAGE; GYNECOLOGIC SURGERY; HEART SURGERY; HUMAN; LIVER CANCER; LIVER SURGERY; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PROSTATECTOMY; SALVAGE THERAPY; SPAIN; SPINE SURGERY; THROMBOELASTOGRAPHY; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; URINARY TRACT CANCER; UROLOGIC SURGERY;

BLOOD TRANSFUSION; CONSENSUS; HUMANS; SPAIN;

EID: 84885672472     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0029-13     Document Type: Conference Paper

References (223)

1. Leal-Noval Sr, Alberca I, Asuero MS, et al. Documento Sevilla de consenso sobre alternativas a la transfusion de sangre alogénica. Med Clín (Barc) 2006; 127 (suppl 1): 3-20.
2. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008; 336: 1049-51.
3. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008; 337: a744.
4. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 2006; 129: 174-81.
5. Hébert PC, Wells G, Blajchman MA, et al. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. A multi- center, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med.1999; 340: 409-17.
6. Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med 2007; 356: 1609-19.
7. Bush RL, Pevec WC, Holcroft JW. A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients. Am J Surg 1997; 174: 143-8.
8. Grover M, Talwalkar S, Casbard A, et al. Silent myocardial ischaemia and Hb concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty. Vox Sang 2006; 90: 105-12.
9. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368: 11-21.
10. Retter A, Wyncoll D, Pearse R, et al. British Committee for Standards in Haematology. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients. Br J Haematol 2013; 160: 445-64.
11. Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. New Engl J Med 2001; 345: 1230-6.
12. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111: 2042-9.
13. Bracey AW, Radovancevic R, Riggs SA, et al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion 1999; 39: 1070-7.
14. Haijar LA, Vincent JL, Galas FRBG, et al. Transfusion requirements after cardiac surgery. The TRACS randomized controlled trial. JAMA 2010; 304: 1559-67.
15. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011; 365: 2453-62.
16. Kramer AH, Zygun DA. Anemia and red blood cell transfusion in neurocritical care. Crit Care 2009; 13: R89.
17. Leal-Noval SR, Múñoz-Gómez M, Murillo-Cabezas F. Optimal hemoglobin concentration in patients with subarachnoid hemorrhage, acute ischemic stroke and traumatic brain injury. Curr Opin Crit Care 2008; 14: 156-62.
18. Carless P, Moxey A, O'Connell D, Henry D. Autologous transfusion techniques: a systematic review of their efficacy. Transf Med 2004; 14: 123-44.
19. Bierbaum BE, Callaghan JJ, Galante JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81: 2-10.
20. Feagan BG, Wong CJ, Johnston WC, et al. Transfusion practices for elective orthopedic surgery. CMAJ 2002; 166: 310-4.
21. Rosencher N, Kerkkamp HE, Macheras G, et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion 2003; 43: 459-69.
22. Freedman J, Luke K, Escobar M, et al. Experience of a network of transfusion coordinators for blood conservation (Ontario Transfusion Coordinators [ONTraC]). Transfusion 2008; 48: 237-50.
23. Keating EM, Callaghan JJ, Ranawat AS, et al. A randomized, parallel-group, open-label trial of recombinant human erythropoietin vs preoperative autologous donation in primary total joint arthroplasty: effect on postoperative vigor and handgrip strength. J Arthroplasty 2007; 22: 325-33.
24. Woolson ST, Wall WW. Autologous blood transfusion after total knee arthroplasty: a randomized, prospective study comparing predonated and postoperative salvage blood. J Arthroplasty 2003; 18: 243-9.
25. Ridgeway S, Tai C, Alton P, et al. Pre-donated autologous blood transfusion in scoliosis surgery. J Bone Joint Surg Br 2003; 85-B: 1032-6.
26. Bess RS, Lenke LG, Bridwell KH, et al. Wasting of preoperatively donated autologous blood in the surgical treatment of adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2006; 31: 2375-80.
27. Franchini M, Gandini G, Regis D, et al. Recombinant human erythropoietin facilitates autologous blood collections in children undergoing corrective spinal surgery. Transfusion 2004; 44: 1122-4.
28. García-Erce JA, Solano VM, Sáez M, Muñoz M. Recombinant human erythropoietin facilitates autologous blood donation in children undergoing corrective spinal surgery. Transfusion 2005;45: 820-1.
29. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang 1998; 75: 128-33.
30. Dietrich W, Thuermel K, Heyde S, et al. Autologous blood donation in cardiac surgery: reduction of allogeneic blood transfusion and cost-effectiveness. J Cardiothorac Vasc Anesth 2005; 19: 589-96.
31. Muñoz M, Campos A, García-Erce JA. Intravenous iron in colorectal cancer surgery. Semin Hematol 2006; 43 (suppl 6): S36-S38.
32. Waters JH, Lee JS, Klein E, et al. Preoperative autologous donation versus cell salvage in the avoidance of allogeneic transfusion in patients undergoing radical retropubic prostatectomy. Anesth Analg 2004; 98: 537-42.
33. Ishizawa T, Hasegawa K, Tsuno NH, et al. Predeposit autologous plasma donation in liver resection for hepatocellular carcinoma: toward allogenic blood-free operations. J Am Coll Surg 2009; 209: 206-14.
34. rd ed. Madrid: Grupo Acción Médica; 2006.
35. Commission Directive 2004/33/EC of 22 March 2004, implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components. Off J Eur Union 2004; L91: 37.
36. Segal JB, Blasco-Colmenares E, Norris EJ, Guallar E. Preoperative acute normovolemic hemodilution: a meta-analysis. Transfusion 2004; 44: 632-44.
37. Mehr-Aein A, Davoodi S, Madani-Civi M. Effects of tranexamic acid and autotransfusion in coronary artery bypass. Asian Cardiovasc Thorac Ann 2007; 15: 49-53.
38. th ed. Barcelona: SETS; 2010.
39. Karkouti K, Beatties WS, Wijeysundera DN, et al. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. Thorac Cardiovasc Surg 2005; 129: 391-400.
40. Wypij D, Jonas RA, Bellinger DC, et al. The effect of hematocrit during hypothermic cardiopulmonary bypass in infant heart surgery: results from the combined Boston hematocrit trials. J Thorac Cardiovasc Surg 2008; 135: 355-60.
41. Bennett J, Haynes S, Torella F, et al. Acute normovolemic hemodilution in moderate blood loss surgery: a randomized controlled trial. Transfusion 2006; 46: 1097-103.
42. Thomas D, Wareham K, Cohen D, Hutchings H. Autologous blood transfusion in total knee replacement surgery. Br J Anaesth 2001; 86: 669-73.
43. Muñoz M, Ariza D, Florez A, Campos A. Reinfusion drains reduce postoperative transfusion requirements after primary total knee replacement surgery. Transfus Med 2008; 18: 269-71.
44. Mirza SB, Campion J, Dixon JH, Panesar SS. Efficacy and economics of postoperative blood salvage in patients undergoing elective total hip replacement. Ann R Coll Surg Engl 2007; 89: 777-84.
45. Trujillo MM, Carrero A, Muñoz M. The utility of the perioperative autologous transfusion system OrthoPAT in total hip replacement surgery: a prospective study. Arch Orthop Trauma Surg 2008; 128: 1031-8.
46. Phillips SJ, Chavan R, Porter ML, et al. Does salvage and tranexamic acid reduce the need for blood transfusion in revision hip surgery? J Bone Joint Surg Br 2006; 88-B: 1141-2.
47. Sebastián C, Romero R, Olalla E, et al. Postoperative blood salvage and reinfusion in spinal surgery: blood quality, effectiveness and impact on patient blood parameters. Eur Spine J 2000; 9: 458-65.
48. Gause PR, Siska PA, Westrick ER, et al. Efficacy of intraoperative cell saver in decreasing postoperative blood transfusions in instrumented posterior lumbar fusion patients. Spine (Phila Pa 1976) 2008; 33: 571-5.
49. Mirza AH, Aldlyami E, Bhimarasetty C, et al. The role of peri-operative cell salvage in instrumented anterior correction of thoracolumbar scoliosis: a case-controlled study. Acta Orthop Belg 2009; 75: 87-93.
50. Rubens FD, Boodhwani M, Mesana T, et al. The cardiotomy trial: a randomized, double-blind study to assess the effect of processing of shed blood during cardiopulmonary bypass on transfusion and neurocognitive function. Circulation 2007; 116 (11 Suppl): I89-97.
51. Murphy GJ, Allen SM, Unsworth-White J, et al. Safety and efficacy of perioperative cell salvage and autotransfusion after coronary artery bypass grafting: a randomized trial. Ann Thorac Surg 2004; 77: 1553-9.
52. Murphy GJ, Rogers CS, Lansdowne WB, et al. Safety, efficacy, and cost of intraoperative cell salvage and autotransfusion after off-pump coronary artery bypass surgery: a randomized trial. J Thorac Cardiovasc Surg 2005; 130: 20-8.
53. Tawfick WA, O'Connor M, Hynes N, Sultan S. Implementation of the Continuous AutoTransfusion System (C.A.T.S) in open abdominal aortic aneurysm repair: an observational comparative cohort study. Vasc Endovascular Surg 2008; 42: 32-9.
54. Serracino-Inglott F, Awad S, Barclay A, Nasim A. The use of a cell saver during repair of ruptured abdominal aortic aneurysms increases early survival [Letter]. Ann R Coll Surg Engl 2005; 87: 475.
55. Donayre C, Adimora U, Song T, et al. Impact of an autotransfusion system during endoluminal repair of abdominal aortic aneurysms: does it decrease the use of allogeneic blood? Am Surg 2005; 71: 786-90.
56. Muscari F, Suc B, Vigouroux D, et al. Blood salvage autotransfusion during transplantation for hepatocarcinoma: does it increase the risk of neoplastic recurrence? Transplant International 2005; 18: 1236-9.
57. Nieder AM, Carmack AJ, Sved PD, et al. Intraoperative cell salvage during radical prostatectomy is not associated with greater biochemical recurrence rate. Urology 2005; 65: 730-4.
58. Liumbruno GM, Liumbruno C, Rafanelli D. Intraoperative cell salvage in obstetrics: is it a real therapeutic option? Transfusion 2011; 51: 2244-56.
59. Bowley DM, Barker P, Boffard KD. Intraoperative blood salvage in penetrating abdominal trauma: a randomised, controlled trial. World J Surg 2006; 30: 1074-80.
60. Muñoz M, Slappendel R, Thomas D. Laboratory characteristics and clinical utility of post-operative cell salvage: washed or unwashed blood transfusion? Blood Transfus 2011; 9: 248-61.
61. Waters JH, Yazer M, Chen YF, Kloke J. Blood salvage and cancer surgery: a meta-analysis of available studies. Transfusion 2012; 52: 2167-73.
62. Johansson PI. Coagulation monitoring of the bleeding traumatized patient. Curr Opin Anesthesiol 2012; 25: 235-41.
63. Kozek-Langeneckerr SA. Perioperative coagulation monitoring. Best Pract Res Clin Anaesth 2010; 24: 27-40.
64. Frith D, Davenport R, Brohi K. Acute traumatic coagulopathy. Curr Opin Anesthesiol 2012; 25: 229-34.
65. Görlinger K, Dirkmann D, Hanke AA, et al. First-line with coagulation factor concentrates combined with poin-of-care coagulation testing is associated with decreased allogeneic Blood transfusion in cardiovascular surgery. Anesthesiology 2011; 115: 1179-91.
66. Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114: 261-74.
67. Afshari A, Wikkelso A, Brok J, et al. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev 2011; 3: CD007871.
68. Kalina U, Bickard H, Schulte S. Biochemical comparison of seven commercially available prothrombin concentrates. Int J Clin Pract 2008; 62: 1614-22.
69. Bhagirath UC, O'Malley L, Crowther MA. Management of bleeding complications in the anticoagulated patient. Semin Hematol 2011; 48: 285-94.
70. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal; a prospective multinational clinical trial; J Thromb Haemost 2008; 6: 622-31.
71. Lankiewicz MW, Hays J, Friedman KD, et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4: 967-70.
72. Lubetsky A, Hoffman R, Zimlichman R, et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004; 113: 371-8.
73. Holbrrok A, Schulman S, Witt DM, et al. Evidence based management of anticoagulant therapy. ACCP guidelines. Chest 2012; 141 (suppl): e152S-e184S.
74. Ferraris VA, Brown JR, Despotis GJ, et al. Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion. International Consortium for Evidence Based Perfusion. Ann Thorac Surg 2011; 91: 944-82.
75. Cucchiara B, Messe S, Sansing L, et al. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008; 39: 2993-6.
76. Flaherty ML, Tao H, Haverbusch M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology 2008; 71: 1084-9.
77. Aiyagari V, Testai FD. Correction of coagulopathy in warfarin associated cerebral hemorrhage. Curr Opin Crit Care 2009; 15: 87-92.
78. Kuwashiro T, Yasaka M, Itabashi R, et al. Enlargement of acute intracerebral hematomas in patients on long-term warfarin treatment. Cerebrovasc Dis 2010; 29: 446-53.
79. Morgenstern LB, Hemphill JD, Anderson C, et al. Guideline for the management of spontaneous intracerebral hemorrhage, AHA/ASA guideline. Stroke 2010; 41: 2108-29.
80. Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood 2011; 117: 6091-9
81. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37: 1465-70.
82. Siddiq F, Jalil A, McDaniel C, et al. Effectiveness of factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage. Neurocrit Care 2008; 8: 36-41.
83. Godier A, Samana CM. Plasma/platelets/red blood cell ratio in the management of the bleeding traumatized patient. Does it matter? Curr Opin Anaesthesiol 2012; 25: 242-7.
84. Dirks J, Jorgensen H, Jensen CH, et al. Blood product ratio in acute traumatic coagulopathy effect in a Scandinavian level 1 trauma center. Scand J Trauma Resusc Emerg Med 2010; 18: 65.
85. Joseph B, Amini A, Friese RS, et al. Factor IX complex for the correction of traumatic coagulopathy. J Trauma Acute Care Surg 2012; 72: 828-34.
86. Schick KS, Fertmann JM, Jauch KW, Hoffmann JN. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K reversal and treatment of severe bleeding. Critical Care 2009; 13: R191.
87. Lorenz R, Kienast J, Otto U, et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol 2003; 15: 15-20.
88. Chowdhury P, Saayman AG, Paulus U, et al. Efficacy of standard dose and 30 ml/Kg fresh frozen plasma in correcting laboratory parameters of haemosthasis in critically ill patients. Br J Haematol 2004; 125: 69-73
89. Leal-Noval SR, Arellano V, Maestre A, et al. Impact of national transfusion indicators on appropriate blood usage in critically ill patients. Transfusion 2011; 51: 1957-65.
90. Illanes S, Zhou W, Schwarting S, et al. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke 2011; 42 : 191-5.
91. Yuan ZH, Jiang JK, Huang WD, et al. A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia. J Clin Neurosc 2010; 17: 685-93.
92. Khorsand N, Veeger NJ, Muller M, et al. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy. Tranfus Med 2011; 21: 116-23.
93. Vigué D. Bench-to-bedside review: optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit Care 2009; R13: 209.
94. Sorensen B, Spahn DR, Innerhofer P, et al. Clinical review: prothrombin complex concentrates, evaluation of safety and Thrombogenicity. Crit Care 2011; 15: 201.
95. Rahe-Meyer N, Sorensen B. Fibrinogen concentrate for management of bleeding. J Thromb Haemost 2011; 9: 1-5.
96. Ozier Y, Hunt BJ. Fibrinogen concentrate for management of bleeding: against indiscriminate use. J Thromb Haemost 2011; 9: 6-8.
97. Solomon C, Koppert W. Schoechl H, et al. Recovery of fibrinogen after administration of fibrinogen concéntrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010; 104: 555-62.
98. Fries D, Martini DZ. Role of fibrinogen in trauma-induced coagulopathy. Br J Anaesth 2010; 105: 116-21.
99. Rossaint R, Bouillon B Management of bleeding following major trauma: an updated European guideline. Crit Care 2010; 14: R52.
100. Stinger HK, Spinella PC, Perkins JG, et al. The ratio of fibrinogen to red blood cell transfused affects survival in casualties receiving massive transfusion at an army combat support hospital. J Trauma 2008; 64: S79-85.
101. Schöchl H, Nienaber U, Maegele M, et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011; 15: R83.
102. Mell MW, O'Neil AS, Callcut RA, et al. Effect of early plasma transfusion on mortality in patients with ruptured abdominal aortic aneurysm. Surgery 2010; 148: 955-62.
103. Lancé MD, Ninivaggi M, Schols SE, et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sang 2012; 103: 25-34.
104. Fenger-Eriksen C, Jensen TM, Kristesen TM, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 2009; 7: 795-802.
105. Bell SF, Rayment R, Collins PW, et al. The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. Int J Obstet Anaesth 2010; 19: 218-23.
106. Weiss G, Lison S, Glaser M, et al. Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register. Blood Coagul Fibrinolysis 2011; 22: 727-34.
107. Ogawa S, Szlam F, Chen EP, et al. A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. Transfusion 2012; 52: 14-22.
108. Fernández-Hinojosa, Murillo-Cabezas F, Puppo-Moreno A, Leal-Noval SR. Alternativas terapéuticas de la hemorragia masiva. Med Intensiva 2012; 36: 496-503.
109. Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 2011; 93-B: 39-46.
110. Alshryda S, Sarda P, Sukeik M, et al. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br 2011; 93-B: 1577-85.
111. Ipema HJ, Tanzi MG. Use of topical tranexamic acid or aminocaproic acid to prevent bleeding after major surgical procedures. Ann Pharmacother 2012; 46: 97-107.
112. Wong J, El Beheiry H, Rampersaud YR, et al. Tranexamic acid reduces perioperative blood loss in adult patients having spinal fusion surgery. Anesth Analg 2008; 107: 1479-86.
113. Elwatidy S, Jamjoom Z, Elgamal E, et al. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. Spine (Phila Pa 1976) 2008; 33: 2577-80.
114. Sethna NF, Zurakowski D, Brustowicz RM, et al. Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology 2005; 102: 727-32.
115. Zufferey P, Merquiol F, Laporte S, et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 2006; 105: 1034-46.
116. Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 2009; 180: 183-93.
117. Adler Ma SC, Brindle W, Burton G, et al. Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2011; 25: 26-35.
118. Abrishami A, Chung F, Wong J. Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. Can J Anaesth 2009; 56: 202-12.
119. Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-31.
120. McIlroy DR, Myles PS, Phillips LE, Smith JA. Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis. Br J Anaesth 2009; 102: 168-78.
121. Molenaar IQ, Warnaar N, Groen H, et al. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2007; 7: 185-94.
122. Wu CC, Ho WM, Cheng SB, et al. Perioperative parenteral tranexamic acid in liver tumor resection: a prospective randomized trial toward a "blood transfusion"-free hepatectomy. Ann Surg 2006; 243: 173-80.
123. Gungorduk K, Yildirim G, Asicioǧlu O, et al. Efficacy of intravenous tranexamic acid in reducing blood loss after elective Cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol 2011; 28: 233-40.
124. Crescenti A, Borghi G, Bignami E, et al. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial. BMJ 2011; 343: d5701.
125. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
126. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg 2012; 147: 113-9.
127. Henry DA, O'Connell DL. Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage. BMJ 1989; 298: 1142-6.
128. Manji RA, Grocott HP, Leake J, et al. Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. Can J Anaesth 2012; 59: 6-13.
129. Montes FR, Pardo DF, Carreño M, et al. Risk factors associated with postoperative seizures in patients undergoing cardiac surgery who received tranexamic acid: a case-control study. Ann Card Anaesth 2012; 15: 6-12.
130. Carless PA, Henry DA, Moxey AJ, et al. Desmopressing for minimimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2004; 1: CD001884
131. Aguado MJ, Molina JM, Villegas R. Appropriate use of recombinant activated factor VII in non-haemophilic patients. Executive summary. Sevilla: Agencia de Evaluación de Tecnologías Sanitarias; 2007. Available at: http://aunets. isciii.es/ficherosproductos/sinproyecto/656-AETSA-2007. Accessed on 31/05/2013.
132. Zangrillo A, Mizzi A, Biondi-Zoccai G, et al. Recombinant activated factor VII in cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2009; 23: 34-40.
133. Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009; 120: 21-7.
134. Hauser CJ, Boffard K, Dutton R, et al CONTROL Study Group. Results of the CONTROL trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. J Trauma 2010; 69: 489-500.
135. Mayer SA, Brun NC, Begtrup K, et al FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127-37.
136. Bosch J, Thabut D, Albillos A, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled study. Hepatology 2008; 47: 1604-14.
137. Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011; 154: 529-40.
138. Diringer MN, Skolnick BE, Mayer SA, et al. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010; 41: 48-53.
139. Levy M, Levy J, Andersen H, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-800.
140. Lidder PG, Sanders G, Whitehead E, et al. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery - a prospective, randomised, controlled trial. Ann R Coll Surg Engl 2007; 89: 418-21.
141. Okuyama M, Ikeda K, Shibata T, et al. Preoperative iron supplementation and intraoperative transfusion during colorectal cancer surgery. Surg Today 2005; 35: 36-40.
142. Cuenca J, Garcia-Erce JA, Martinez F, et al. Preoperative haematinics and transfusion protocol reduce the need for transfusion after total knee replacement. Int J Surg 2007; 5: 89-94.
143. Rogers BA, Cowie A, Alcock C, Rosson JW. Identification and treatment of anaemia in patients awaiting hip replacement. Ann R Coll Surg Engl 2008; 90: 504-7.
144. Mundy GM, Birtwistle SJ, Power RA. The effect of iron supplementation on the level of Hb after lower limb arthroplasty J Bone Joint Surg Br 2005; 87-B: 213-7.
145. Parker MJ. Iron supplementation for anemia after hip fracture surgery: a randomized trial of 300 patients. J Bone Joint Surg Am 2010; 92-A: 265-9.
146. Crosby L, Palarski VA, Cottington E, Cmolik B. Iron supplementation for acute blood loss anemia after coronary artery bypass surgery: a randomized, placebo-controlled study. Heart Lung 1994; 23: 493-9.
147. Pieracci FM, Henderson P, Macmillan R Jr, et al. Randomized, double-blind, placebo-controlled trial of effects of enteral iron supplementation on anemia and risk of infection during surgical critical illness. Surg Infect 2009; 10: 9-19.
148. Bisbe E, García-Erce JA, Díez-Lobo AI, Muñoz M. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth 2011; 107: 477-8.
149. Díaz-Espallardo C, Laso-Morales MJ, Colilles-Calvet C, et al. El abordaje multidisciplinar es útil para la optimización de la hemoglobina preoperatoria en cirugía neoplásica colorrectal. Cir Esp 2011; 89: 392-9.
150. Edwards TJ, Noble EJ, Durran A, et al. Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br J Surg 2009; 96: 1122-8.
151. Cuenca J, Garcia-Erce JA, Muñoz M, et al. Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: a pilot study. Transfusion 2004; 44: 1447-52.
152. Cuenca J, Garcia-Erce JA, Martinez AA, et al. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: preliminary data. Arch Orthop Trauma Surg 2005; 125: 342-7.
153. Serrano-Trenas JA, Font-Ugalde P, Muñoz-Cabello L, et al. Role of perioperative intravenous iron therapy in elderly hip fracture patients. A single center randomized controlled trial. Transfusion 2010; 51: 97-104.
154. García-Erce JA, Cuenca J, Muñoz M, et al. Perioperative stimulation of erythropoiesis with intravenous iron and erythropoietin reduces transfusion requirements in patients with hip fracture. A prospective observational study. Vox Sang 2005; 88: 235-43.
155. García-Erce JA, Cuenca J, Haman-Alcober S, et al. Efficacy of preoperative recombinant human erythropoietin administration for reducing transfusion requirements in patients undergoing surgery for hip fracture repair. An observational cohort study. Vox Sang 2009; 97: 260-7.
156. Cuenca J, Garcia-Erce JA, Martinez F, et al. Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogenic blood after knee replacement surgery. Transfusion 2006; 46: 1112-9.
157. Madi-Jebara SN, Sleilaty GS, Achouh PE, et al. Postoperative intravenous iron used alone or in combination with low-dose erythropietin is not effective for correction of anemia after cardiac surgery. J Cardiothorac Vasc Anesth 2004; 18: 59-63.
158. Muñoz M, Naveira E, Seara J, Cordero J. Effects of postoperative intravenous iron on transfusion requirements after lower limb arthroplasty. Br J Anaesth 2012; 108: 532-4.
159. Berniére J, Dehullu JP, Gall O, Murat I. Le fer intraveineux dans le traitement des anémies postopératoires dans la chirurgie du rachis de l'enfant et de l'adolescent. Rev Chir Orthop Reparatrice Appar Mot 1998; 84: 319-22.
160. Gredilla E, Gimeno M, Canser E, et al. Tratamiento de la anemia en el postparto y en el postoperatorio inmediato de cirugía ginecológica, con hierro intravenoso. Rev Esp Anestesiol Reanim 2006; 53: 208-13.
161. Armand-Ugón R, Cheong T, Matapandewu G, et al. Efficacy of intravenous iron for treating postpartum anemia in low-resource African countries: a pilot study in Malawi. J Womens Health (Larchmt) 2011; 20: 123-7.
162. Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. BJOG 2006; 113: 1248-52.
163. Westad S, Backe B, Salvesen KA, et al. A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia. Acta Obstet Gynecol Scand 2008; 87: 916-23.
164. Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007; 110: 267-78.
165. Seid MH, Derman RJ, Baker JB, et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008; 199: 435.e1-7.
166. Schröder O, Mickisch O, Seidler UH, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005; 100: 2503-9.
167. Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009: 44; 838-45.
168. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-92.
169. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846-53.
170. Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007; 105: 199-204.
171. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010; 116: 522-5.
172. García-Erce JA, Fernández C, Lao J, Muñoz M. Meta-análisis de la eficacia y seguridad de hierro endovenoso en el tratamiento de la anemia, en pacientes oncológicos tratados con agentes estimulantes de la eritropoyesis. Haematologica (Spanish edition) 2009; 94 (extra 2): 138.
173. Hedenus M, Birgegård G, Näsman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627-32.
174. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-82.
175. Stainsby D, Jones H, Asher D, et al. Serious Hazards of Transfusion: A Decade of Hemovigilance in the UK. Transfus Med Rev 2006; 20: 272-82.
176. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-32.
177. Harju E. Empty iron stores as a significant risk factor in abdominal surgery. J Parent Enteral Nutr 1988; 12: 282-5.
178. Izuel-Rami M, García-Erce JA, Gómez-Barrera M, et al. Relación entre la transfusión de sangre alogénica, la deficiencia de hierro y la infección nosocomial en pacientes con fractura de cadera. Med Clin (Barc) 2008; 131: 647-52.
179. Laupacis A, Fergusson D. Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomized trials. Transfus Med 1998; 8: 309-17.
180. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000; 133: 845-54.
181. Weber EWG, Slappendel R, Hémon Y, et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005; 22; 249-57.
182. Karkouti K, McCluskey SA, Evans L, et al. Erythropoietin is an effective clinical modality for reducing RBC transfusion in joint surgery. Can J Anesth 2005; 52: 363-8.
183. Alghamdi AA, Albanna MJ, Guru V, Brister SJ. Does the use of erythropoietin reduce the risk of exposure to allogeneic blood transfusion in cardiac surgery? A systematic review and meta-analysis. J Card Surg 2006; 21: 320-6.
184. Ootaki Y, Yamaguchi M, Yoshimura N, et al. The efficacy of preoperative administration of a single dose of recombinant human erythropoietin in pediatric cardiac surgery. Heart Surg Forum 2007; 10: E115-9.
185. Weltert L, D'Alessandro S, Nardella S, et al. Preoperative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: a randomized blind controlled study. J Thorac Cardiovasc Surg 2010; 139: 621-6.
186. Yoo YC, Shim KK, Kim JC, et al. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 2011; 115: 929-37.
187. Qvist N, Boesby S, Wolf B, Hansen CP. Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative periods: reduced nee for blood transfusions in patients undergoing colorectal surgery - Prospective double-blind placebo-controlled study. World J Surg 1999; 23: 30-5.
188. Kosmadakis N, Messaris E, Maris A, et al. Perioperative erythropioietin administration in patients with gastrointestinal tract cancer. Prospective randomized double blind study. Ann Surg 2003; 237: 417-21.
189. Christodoulakis M, Tsiftsis DD, for the Hellenic Surgical Oncology Perioperative EPO Study Group. Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study. Ann Surg Oncol 2005; 12: 718-25.
190. Zarychansky R, Turgeron AB, McIntyre L, Fergusson DA. Erythropoietin-receptor agonist in critical ill patients: A meta-analysis of randomised controlled trials. CMAJ 2007; 177: 725-34.
191. Muñoz M, García-Erce JA, Leal-Noval SR. ¿La eritropoyetina humana recombinante es aún una alternativa válida para el tratamiento de la anemia del paciente crítico? Med Clin (Barc) 2009; 132: 749-55.
192. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357: 965-76.
193. Talving P, Lustenberger T, Inaba K, et al. Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: a prospective study. Arch Surg 2012; 147: 251-5.
194. Rosencher N, Poisson D, Albi A, et al. Two injections of erythropoietin correct moderate anemia in most patients awaiting orthopedic surgery. Can J Anesth 2005; 52: 160-5.
195. Gonzalez-Porras JR, Colado E, Conde MP, et al. An individualized pre-operative blood saving protocol can increase pre-operative Hb levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med 2009; 19: 35-42.
196. Stowell CP, Jones SC, Enny C, et al. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Spine (Phila Pa 1976) 2009; 34: 2479-85.
197. Dahl NV, Henry DH, Coyne DW. Thrombosis with erythropoietic stimulating agents: does iron-deficient erythropoiesis play a role? Semin Dial 2008; 21: 210-1.
198. Basora M, Fita G, Matute P, Díaz-Ricart M. Safety concerns about perisurgical epoetin treatment: should we add antiplatelet drugs to perisurgical epoetin alfa treatment? J Cardiothorac Vasc Anesth 2007; 21: 623-4.
199. Roberts I, Alderson P, Bunn F, et al. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2004; 4: CD000567.
200. Pargger H, Studer W, Ruttimann U. Volume therapy in hypotensive trauma patients. Schweiz Med Wochenschr 2000; 130: 1509-15.
201. Soreide E, Deakin CD. Pre-hospital fluid therapy in the critically injured patient - a clinical update. Injury 2005; 36: 1001-10.
202. Nolan J. Fluid resuscitation for the trauma patient. Resuscitation 2001; 48: 57-69.
203. Shafi S, Kauder DR. Fluid resuscitation and blood replacement in patients with polytrauma. Clin Orthop Relat Res 2004; 422: 37-42.
204. Santry HP, Alam HB. Fluid resuscitation: past, present, and the future. Shock 2010; 33: 229-41.
205. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg 2008; 107: 382-90.
206. Stainsby D, MacLennan S, Thomas D, et al. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135: 634-41.
207. Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248: 447-58.
208. Nakstad AR, Skaga NO, Pillgram-Larsen J et al. Trends in transfusion of trauma victims - evaluation of changes in clinical practice. Scand J Trauma Resusc Emerg Med 2011; 11: 19-23.
209. Rajasekhar A, Gowing R, Zarychanski R, et al. Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio. Critical Care Medicine 2011; 39: 1507-13.
210. Nascimento B, Callum J, Rubenfeld G, et al. Clinical review: fresh frozen plasma in massive bleedings - more questions than answers. Crit Care 2010; 14: 202.
211. Stansbury LG, Dutton RP, Stein DM, et al. Controversy in trauma resuscitation: do ratios of plasma to red blood cells matter? Transfus Med Rev 2009; 23: 255-65.
212. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2007; 4: CD000567.
213. Perner A, Haase N, Guttormse AB, et al. Hydroxyethyl starch 130/0.4 versus Ringer acetate in severe sepsis. N Engl J Med 2012; 367: 124-34.
214. Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367: 1901-11.
215. Riess JG. Perfluorocarbon-based oxygen delivery. Artif Cell Blood Substit Biotechnol 2006; 34: 567-80.
216. Maevsky E, Ivanitsky G, Bogdanova L, et al. Clinical results of Perftoran application: present and future. Artif Cell Blood Substit Biotechnol 2005; 33: 37-46.
217. Cohn CS, Cushing MM. Oxygen therapeutics: perfluorocarbons and blood substitute safety. Crit Care Clin 2009; 25: 399-414.
218. Verdín-Vasquez RC, Zepeda-Pérez C, Ferra-Ferrer R, et al. Use of perftoran emulsion to decrease allogeneic blood transfusion in cardiac surgery: clinical trial. Artif Cell Blood Substit Biotechnol 2006; 34: 433-54.
219. Jahr JS, Mackenzie C, Pearce LB, et al. HBOC-201 as an alternative to blood transfusion: Efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma 2008; 64: 1484-97.
220. Cothern C, Moore EE, Offner PJ, et al. Blood substitute and erythropoietin therapy in severely anemic Jehovah's Witness. N Engl J Med 2002; 346: 1097-8.
221. Moore EE, Moore FA, Fabian TC, et al. human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. J Am Coll Surg 2009; 208: 1-13.
222. Olofsson C, Nygards EB, Ponzer S, et al. A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan) administered to orthopaedic surgery patients with spinal anaesthesia. Transfus Med 2008; 18: 28-39.
223. Silverman TA, Weiskopf RB. Hemoglobin-based oxygen carriers: current status and future directions. Anesthesiology 2009; 111: 946-63.